Indaptus Therapeutics
INDP
36 hedge funds and large institutions have $80.9M invested in Indaptus Therapeutics in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 9 reducing their positions, and 4 closing their positions.
175% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 4
78% more call options, than puts
Call options by funds: $508K | Put options by funds: $285K
20% more funds holding
Funds holding: 30 → 36 (+6)
10% less capital invested
Capital invested by funds: $90.1M → $80.9M (-$9.19M)
44% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$963K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$280K |
| 3 |
MC
Menta Capital
San Francisco,
California
|
+$263K |
| 4 |
PC
PA Capital
Richmond,
Virginia
|
+$245K |
| 5 |
Morgan Stanley
New York
|
+$210K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$4.66M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.33M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
-$1.05M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$648K |
| 5 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$318K |
INDP Hedge Fund Activity: Q1 2019 in Review
36 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q1 2019, worth a combined $80.9M — down 10% from $90.1M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new INDP positions and 4 closed out — a net gain of 7 holders — while 5 added to existing stakes and 9 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $963K. The largest seller was Harel Insurance Investments & Financial Services, cutting an estimated $4.66M.
- 36 institutional investors held Indaptus Therapeutics (INDP) as of Q1 2019, up from 30 in Q4 2018.
- Funds reported $80.9M of Indaptus Therapeutics stock for Q1 2019, down 10% quarter-over-quarter.
- 11 funds opened new Indaptus Therapeutics positions in Q1 2019 and 4 closed out, a net change of +7 holders.
- The largest Indaptus Therapeutics buyer in Q1 2019 was Susquehanna International Group, an estimated $963K added.
- The largest Indaptus Therapeutics seller in Q1 2019 was Harel Insurance Investments & Financial Services, an estimated $4.66M sold.
Based on aggregated 13F filings for Q1 2019.